Last update 05 Feb 2026

ExoRNA Bioscience Nanjing Co. Ltd.

Subsidiary Company|2021|Jiangsu Sheng, China

Overview

Basic Info

Introduction
ExoRNA Bioscience Nanjing Co. Ltd., co-founded in September 2021 by Professor Zhang Chenyu and Dr. Meng Xia, is headquartered in Shenzhen, with subsidiaries in Nanjing and Shanghai. Focused on developing drugs for diseases without cure and unmet clinical needs, particularly in the central nervous system, ExoRNA aspires to become a global leader in platform-based innovative nucleic acid therapeutics. The company boasts a unique self-assembling exosome nucleic acid delivery platform with multiple organ targeting capabilities, the ability to cross the blood-brain barrier, high safety, and low cost, offering an all-in-one solution to current RNA drug delivery challenges.

Tags

Nervous System Diseases
Other Diseases
Congenital Disorders
Exosomes
siRNA

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Nervous System Diseases1
Top 5 Drug TypeCount
Exosomes1
siRNA1
Top 5 TargetCount
LAMP-2(Lysosome-associated membrane glycoprotein 2)1

Related

1
Drugs associated with ExoRNA Bioscience Nanjing Co. Ltd.
ER-2001
Target
LAMP-2
Mechanism
LAMP-2 inhibitors
Active Org.
ExoRNA Bioscience Nanjing Co. Ltd.
Originator Org.
ExoRNA Bioscience Nanjing Co. Ltd.
Active Indication
Huntington Disease
Inactive Indication-
Drug Highest PhasePhase 1/2
First Approval Ctry. / Loc.-
First Approval Date-
3
Clinical Trials associated with ExoRNA Bioscience Nanjing Co. Ltd.
NCT07339514
/ Active, not recruitingPhase 1/2
A Randomized, Double-Blind, Placebo-Controlled Phase I Clinical Study of ER2001 Intravenous Injection in Adults With Early Manifest Huntington's Disease.
NCT07344519
/ Active, not recruitingEarly Phase 1
Open-Label, Dose Escalation Early Phase 1 Study of ER2001 Intravenous Injection Repetitive Treatment in Adults With Early Manifest Huntington's Disease.
NCT06024265
/ CompletedEarly Phase 1
An Open-Label, Dose Escalation Early Phase 1 Study of ER2001 Intravenous Injection in Adults With Early Manifest Huntington's Disease
100 Clinical Results associated with ExoRNA Bioscience Nanjing Co. Ltd.
Login to view more data
0 Patents (Medical) associated with ExoRNA Bioscience Nanjing Co. Ltd.
Login to view more data
100 Deals associated with ExoRNA Bioscience Nanjing Co. Ltd.
Login to view more data
100 Translational Medicine associated with ExoRNA Bioscience Nanjing Co. Ltd.
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 08 Feb 2026

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Phase 2
1
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
ER-2001
 ( LAMP-2 )		Huntington Disease
More
Phase 1/2
Login to view more data

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free